Search

Your search keyword '"Junghanss, Christian"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Junghanss, Christian" Remove constraint Author: "Junghanss, Christian" Journal blood Remove constraint Journal: blood
44 results on '"Junghanss, Christian"'

Search Results

1. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

2. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

3. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

4. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

5. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

6. Phenotypes of JAK2-Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

7. Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

8. Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation – a National Multicenter Study

10. The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

11. Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

12. Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

13. Hypomethylating Agents and Casein Kinase 2 Inhibitor Act Synergistic and Reveal Significant Anti-Leukemic Effects in Acute Lymphoblastic Leukemia Cells

14. Impact of Infusion Rate on the Early Engraftment Following Allogeneic Intra Bone Marrow Infusion of Hematopoietic Stem Cells in a Canine DLA-Identical Reduced Intensity Transplantation Model

15. Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

16. Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

17. Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

18. Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

19. Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia

20. Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained after Double Stem Cell Transplant

21. Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)

22. Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

23. Engraftment Effects of Intra Bone Marrow Compared to Intravenous Transplantation of Allogeneic Hematopoietic Stem Cells Following a Reduced Intensity Conditioning in a DLA-Identical Canine Littermate Model

24. Polymorphism nt7778G/T In Mitochondrial ATP8 Gene Promotes Protective Effect On Reactive Oxygen Species Level In Murine Hematopoietic Cells During Aging

27. Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years

28. Prognostic Factors For Overall Survival In Elderly Patients With Relapsed Acute Myeloid Leukemia – Retrospective Study On Behalf Of The East German Study Group For Hematology and Oncology (OSHO)

29. Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL),

31. Intra-Bone Marrow Transplantation of CD34+ Enriched Grafts Following a Non-Myeloablative Conditioning Allows Successful Engraftment In DLA-Identical Canine Litters.

32. Low Levels of Global (LINE) and CDH13 Methylation at Diagnosis and Rapid Clearance of Marrow Blasts Correlate with A Better Haematological Response to Azacitidine in Patients with Newly Diagnosed and Refractory/Relapsed AML Not Eligible for or Resistant to Chemotherapy: A Multi-Centre Phase I/II-Study of the East German Haematology and Oncology Study Group (OSHO).

33. Reduction of Relapse Incidence and Improvement of Leukemia Free Survival by Allogeneic Stem Cell Transplantation in Patients with AML and Normal Karyotype Irrespective of the FLT3-ITD Status.

34. Experience with a Therapeutic Platelet Transfusion Strategy in Acute Myeloid Leukemia: Preliminary Results of a Randomized Multicenter Study After Enrolment of 175 Patients.

37. Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

38. Severity of Chronic Gvhd and Personality Determines Quality of Life and the Activity Profile: Results of a Prospective German Multicenter Validation Trial

42. Allogeneic Blood Stem Cell Transplantation in Patients with Hematologic Diseases after Conditioning with Treosulfan and Fludarabine.

43. Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells

44. Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De NovoPhiladelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

Catalog

Books, media, physical & digital resources